Drug repurposing aims to discover new indications for existing drugs with known safety profiles. The advent of high-throughput technologies to systematically evaluate drug effects across different cellular contexts enables such discoveries. However, determining a complete list of clinical drugs and obtaining these compounds for laboratory use is surprisingly challenging. To address this challenge, we integrated multiple public and proprietary data sources with chemical vendor catalogs.
The Drug Repurposing Hub is a close collaboration between the Broad Institute Cancer Program, Center for the Development of Therapeutics, and the Connectivity Map group.
More than 8,000 compound samples were purchased from 50 different suppliers. Each compound has been assayed for purity, registered in the Broad compound management system, and annotated for structure, clinical development status, vendor information, mechanism of action, protein targets, and approved indications. Explore library contents now via the Repurposing Hub web application.
We do not offer copies of the library for purchase. However, we collaborate with many groups, both at the Broad and non-Broad affiliates,. If you are interested in collaborating, please email email@example.com.
No, the annotations provided in the hub are freely available for research use by any organization. The information in the Repurposing Hub may not be repackaged or redistributed for commercial purposes without permission.
No. The drug library created as part of the repurposing hub is being profiled by other projects such as the Connectivity Map and LINCS. Please review project websites for information on data release.
The dataset available in the Repurposing Hub contains comprehensive annotations for a total of 5627 compounds: 2,350 FDA-approved drugs, 1,600 drugs that reached phases 1-3 of clinical development, 95 compounds that were previously approved but withdrawn from use, and 1,582 preclinical or tool compounds. Annotations specifically include compound name, chemical structure, clinical trial status, mechanism of action, protein targets, disease areas, approved indications (where applicable), purity of the purchased sample, and vendor ID.
The information in the Repurposing Hub may not be repackaged or redistributed for commercial purposes without permission.
The Repurposing Hub annotations are available via a RESTful web service as part of the Connectivity Map CLUE compute platform. See here for the CLUE API.
Note that to download repurposing annotation in batch format, the Drug information and Sample information downloadable files (see above) have relevant information and you do not need the API.
Several proprietary databases were used in the initial library design and summary analyses. Due to licensing restrictions we cannot provide exports from these resources.
We thank the curators of public drug databases, our chemical vendors, and assay teams. We gratefully acknowledge funding sources including the Broad Next10 initiative, NIH LINCS Program grant 3U54 HG006093, NIH BD2K Program grant 5U01HG008699, NIH training grant T32 CA009172, NIH/Harvard Catalyst training award KL2 TR001100, and Conquer Cancer Foundation of ASCO Young Investigator Award.
Please cite usage as: Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, Johnston SE, Vrcic A, Wong B, Khan M, Asiedu J, Narayan R, Mader CC, Subramanian A, Golub TR. The Drug Repurposing Hub: a next-generation drug library and information resource. Nature Medicine. 23, 405–408 (2017). Online view only access via Springer Nature SharedIt is here.